Resource Summary Report

Generated by RRID on Aug 31, 2026

Phospho-Chk1 (Ser345) (133D3) Rabbit mAb

RRID:AB_331212
Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 2348, RRID:AB_331212

Antibody Information

URL: http://antibodyregistry.org/AB_331212

Proper Citation: Cell Signaling Technology Cat# 2348, RRID:AB_331212

Target Antigen: Chk1, phospho (Ser345)

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: W, IF-IC, F. Consolidation: AB_2080326, AB_10079109.

Antibody Name: Phospho-Chk1 (Ser345) (133D3) Rabbit mAb

Description: This monoclonal targets Chk1, phospho (Ser345)

Target Organism: monkey, rat, mouse, human

Clone ID: 133D3

Defining Citation: PMID:28017544

Antibody ID: AB_331212

Vendor: Cell Signaling Technology

Catalog Number: 2348

Alternative Catalog Numbers: 2348P, 2348S, 2348T, 2348L

Record Creation Time: 20250819T233908+0000

Record Last Update: 20250820T055958+0000

Ratings and Alerts

No rating or validation information has been found for Phospho-Chk1 (Ser345) (133D3) Rabbit mAb.

No alerts have been found for Phospho-Chk1 (Ser345) (133D3) Rabbit mAb.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 190 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

Wang Q, et al. (2026) FANCA-dependent FEN1 recruitment suppresses transcription-replication conflicts and PARPi sensitivity. Molecular cell.

Wang H, et al. (2026) Targeting the ER?? DBD-LBD Interface with Mitoxantrone Disrupts Receptor Function through Proteasomal Degradation. Molecular cancer therapeutics, 25(1), 107.

Guo J, et al. (2026) The cytotoxic effect of prexasertib is a consequence of dual inhibition on both CHK1 and AMPK. Cell chemical biology, 33(6), 767.

Koppenhafer SL, et al. (2026) DNA replication stress and translational repression converge to drive CDK1- and caspase-dependent apoptosis in Ewing sarcoma. Oncogene, 45(28), 2823.

Zhou Z, et al. (2026) SUDS3 nuclear condensates decelerate DNA replication and safeguard genome stability. Cell reports, 45(7), 117713.

Xu G, et al. (2026) Delactylation of the tumor suppressor ARHGDIB drives metastasis and chemoresistance in bladder cancer. Cell reports, 45(2), 116941.

Ma Y, et al. (2026) Exploiting the polypharmacology of alectinib for synergistic RNA splicing disruption with RBM39 degraders. Cell reports, 45(1), 116784.

Young TM, et al. (2026) CF10 Displays Improved Synergy with Oxaliplatin in TP53-Null and Wild-Type CRC Cells from Increased Top1cc and Replication Stress. Cancers, 18(5).

Ialchina R, et al. (2026) Microenvironmental acidosis drives PARP- and ATM inhibitor resistance in p53 deficient pancreatic cancer. iScience, 29(3), 115112.

Hurley K, et al. (2026) PARP1 recruits SPRTN to DNA-protein crosslinks through a conserved poly-ADP-ribose binding domain. bioRxiv : the preprint server for biology.

Aussel A, et al. (2026) Tumor metabolic adaptation induced by L-asparaginase reveals a vulnerability to PARP1/2 inhibitor in B-cell lymphomas. Nature communications, 17(1).

Gracilla DE, et al. (2026) FET Fusion Oncoproteins Disrupt Physiologic DNA Repair and Create a Targetable Opportunity for ATR Inhibitor Therapy. Cancer research, 86(11), 2660.

Planchard D, et al. (2026) Efficacy, safety, and biomarker analysis of datopotamab deruxtecan in advanced non-small cell lung cancer: ICARUS-LUNG01 phase 2 study. Cancer cell, 44(6), 1147.

Spindler J, et al. (2026) SLX4IP limits replication stress globally and at ALT telomeres. The EMBO journal, 45(12), 4176.

Cui S, et al. (2026) Ski2-like helicase ASCC3 unwinds DNA upon fork stalling to control replication stress responses. Cell reports, 45(3), 117051.

Wang D, et al. (2026) PRMT5 is Frequently Upregulated and a Potential Therapeutic Target in MTAP-deficient Malignant Peripheral Nerve Sheath Tumors. bioRxiv : the preprint server for biology.

Planas-Paz L, et al. (2026) Targeting ATR signaling in sarcoma with homologous recombination deficiency. Cancer letters, 642, 218300.

Guo X, et al. (2026) The WEE1 inhibitor azenosertib broadly enhances efficacy of antibody-drug conjugates with topoisomerase I and microtubule inhibitor payloads. iScience, 29(7), 116390.

Tian M, et al. (2026) Targeted antibody-drug conjugates for rhabdomyosarcoma and other FGFR4-expressing cancers. Cell reports. Medicine, 7(7), 102922.

Joyce CM, et al. (2026) The FANCD2-FANCI heterodimer coordinates chromatin openness and cell cycle progression throughout DNA double-strand break repair. Cell reports, 45(1), 116830.